Explore /
Poster
/ Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin)-treated patients with metastatic pancreatic cancer: The randomized phase II PAN1 study.

Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin)-treated patients with metastatic pancreatic cancer: The randomized phase II PAN1 study.

Authors

Yu Jo Chua

The Canberra Hospital, Garran, Australia

Yu Jo Chua , Christos Stelios Karapetis , Val Gebski , Rachel O'Connell , Stephen Begbie , Louise M. Nott , Michelle F. Cronk , Craig Underhill , Ehtesham A. Abdi , Thomas Van Hagen , Nicole Wong , Merryn Hall , Danielle Angela Ferraro , Katrin Marie Sjoquist , Cheryl Santos , John Robert Mackey , David Goldstein

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2014 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Translational Research

Clinical Trial Registration Number

ACTRN12610001047088

Citation

J Clin Oncol 32, 2014 (suppl 3; abstr 228)

DOI

10.1200/jco.2014.32.3_suppl.228

Abstract #

228

Poster Bd #

Abstract Disclosures

Similar Posters

Poster

2020 ASCO Virtual Scientific Program

$A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.$